The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.
 
Weijian Guo
No Relationships to Disclose
 
Xiaodong Zhu
No Relationships to Disclose
 
Mingzhu Huang
No Relationships to Disclose
 
Yusheng Wang
No Relationships to Disclose
 
Zhiyu Chen
No Relationships to Disclose
 
Wanjing Feng
No Relationships to Disclose
 
Yifu He
No Relationships to Disclose
 
Xiaowei Zhang
No Relationships to Disclose
 
Xin Liu
No Relationships to Disclose
 
Chenchen Wang
No Relationships to Disclose
 
Wen Zhang
No Relationships to Disclose
 
Jieer Ying
No Relationships to Disclose
 
Jun Wu
No Relationships to Disclose
 
Lei Yang
No Relationships to Disclose
 
Yanru Qin
No Relationships to Disclose
 
Xiaoying Zhao
No Relationships to Disclose
 
Wenhua Li
No Relationships to Disclose
 
Zhe Zhang
No Relationships to Disclose
 
Lixin Qiu
No Relationships to Disclose
 
XiaoFeng Wang
No Relationships to Disclose